ABBV RSI

What is ABBV?

AbbVie officially launched in 2013 as a spin-off from Abbott Laboratories, designed to be an agile, research-driven biopharmaceutical company. Its founding mission was to leverage a deep pipeline of specialty medicines to treat some of the world’s most challenging health conditions. Today, the business model is centered on high-margin therapeutic areas where innovation can command significant market share and long-term patent protection.

The company’s product lineup is legendary, headlined for years by Humira, which was the top-selling drug globally for a decade. As Humira faced patent expiration, AbbVie successfully launched Skyrizi and Rinvoq, which are now leaders in treating plaque psoriasis and rheumatoid arthritis. Their 2020 acquisition of Allergan was a massive milestone, diversifying their revenue streams into aesthetics with Botox and Juvederm, as well as neuroscience. This move significantly reduced their dependence on a single blockbuster drug and solidified their presence in the elective medical procedure market.

From a financial standpoint, AbbVie is a powerhouse known for its Dividend Aristocrat status. Despite the patent cliff concerns that loomed over the company for years, they have maintained impressive operating margins and robust free cash flow. This financial flexibility has allowed them to continue a streak of strategic acquisitions, such as the recent purchases of ImmunoGen and Cerevel Therapeutics, which bolster their oncology and psychiatric medicine portfolios respectively.

Looking ahead to 2026, the strategic outlook is incredibly bright and represents a major turning point. The company expects to see a return to robust operational growth as the erosion of Humira sales finally finds its floor and stabilizes. By 2026, the scaling of their newer immunology blockbuster drugs, combined with a revitalized oncology pipeline and a dominant position in aesthetics, should drive significant shareholder value and dividend growth. Management is laser-focused on total top-line growth, aiming to prove that their post-Humira era will be even more profitable than the decade that preceded it.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For ABBV, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, ABBVIE INC. is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding ABBV RSI Signals

• Oversold (RSI below 30): When ABBV RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates ABBV may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When ABBV price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for ABBV

This page displays both daily and weekly RSI for ABBV. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand ABBVIE INC.'s momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when ABBV RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how ABBVIE INC. has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.